MARKET

CCCC

CCCC

C4 Therapeutics, Inc.
NASDAQ
4.240
+0.190
+4.69%
After Hours: 4.370 +0.13 +3.07% 19:56 06/21 EDT
OPEN
4.070
PREV CLOSE
4.050
HIGH
4.360
LOW
4.060
VOLUME
8.88M
TURNOVER
0
52 WEEK HIGH
11.88
52 WEEK LOW
1.060
MARKET CAP
291.74M
P/E (TTM)
-1.7859
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CCCC last week (0610-0614)?
Weekly Report · 6d ago
C4 Therapeutics: Losing Steam And Presenting An Opportunity
C4 Therapeutics is a developmental biotech focused on protein degraders. The pipeline includes Cemsidomide for multiple myeloma and CFT1946 for melanoma, with ongoing dose escalation trials. The company reported $279.6 million in current assets, with a cash runway of approximately 9 to 10 quarters.
Seeking Alpha · 06/13 15:33
C4 Therapeutics Appoints Mr. Cooper to Board
TipRanks · 06/10 12:05
C4 Therapeutics Taps Ron Cooper of Albireo Pharma as Board Chair Succeeding Bruce Downey
C4 Therapeutics, Inc. Announces changes to its Board of Directors. Ron Cooper, a global biopharmaceutical executive, has been appointed chairman of the board. Glenn Dubin has decided to step down from the board of directors. C4T is dedicated to advancing targeted protein degradation science.
Benzinga · 06/10 11:48
*C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors >CCCC
Dow Jones · 06/10 11:01
C4 THERAPEUTICS APPOINTS RON COOPER AS CHAIRMAN OF THE BOARD OF DIRECTORS
Reuters · 06/10 11:00
Press Release: C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
Dow Jones · 06/10 11:00
Weekly Report: what happened at CCCC last week (0603-0607)?
Weekly Report · 06/10 09:02
More
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.

Webull offers C4 Therapeutics Inc stock information, including NASDAQ: CCCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CCCC stock methods without spending real money on the virtual paper trading platform.